Search results
Results From The WOW.Com Content Network
Patheon was founded in Fort Erie, Ontario in 1974 as Custom Pharmaceuticals Ltd. In 1990, it began to expand to US markets. Custom Pharmaceuticals changed its name to Patheon in 1993 and was first publicly traded that year on the Toronto Stock Exchange. [1] In 2004, Patheon acquired MOVA, a drug manufacturer based in Puerto Rico, US.
The company's products are sold under the brand names of Thermo Scientific, Fisher Scientific, and several other recognized brand names (e.g. Applied Biosystems, Invitrogen, Patheon, PPD, and Nalgene). According to company figures, as of 2007, 46% of its sales were in life sciences, 20% in healthcare, and 34% in industrial/environmental and safety.
WuXi PharmaTech was founded in December 2000 in Shanghai by organic chemist Ge Li. [1] [2]The company opened chemistry facilities in Tianjin in 2007. In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA.
WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. [6] As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. [7] In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. [8]
Yu invented and developed three "Class I" drugs in China. [10] He invented Oncorine (an oncology product), [11] which is the world's first oncolytic virus product; [12] Tyvyt (generic name: sintilimab), which is the domestically developed PD-1 antibody jointly developed by Innovent Biologics and Eli Lilly and Company, [13] and the key clinical results of Tyvyt in patients with r/r cHL have ...
Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
The optimization of hardware and software allowed the company to bring model training costs down from $100 million to $5 million, 100,000 to 2,000 GPUs, and reduce API costs by 95 percent ...
The company was listed on the New York Stock Exchange before going public in Hong Kong in 2018. [11] [12] In 2011, Li was named a member of the Committee of One Hundred. [13] As of 2022, his net worth was estimated at $10 billion, making him one of the richest men in China and the United States.